Boundless Bio Q1 2026 net loss $13.6M; cash $92.8M provides runway into H2 2028

Boundless Bio, Inc.

2026-Q1 EPS reported -$0.60

Cash, cash equivalents, and short-term investments $92.8M as of March 31, 2026.
Net loss $13.6M vs $15.8M in Q1 2025; R&D expense $9.7M vs $12.1M.
KOMODO-1 first-in-human trial of BBI-940 enrolling patients with ER+/HER2- and TNBC-LAR breast cancer.
AACR 2026 data showed tumor regression from BBI-940 in ecDNA+ TNBC-LAR and ER+ breast cancer models.
G&A expense $4.7M vs $5.2M year-over-year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Boundless Bio, Inc. reported the fiscal quarter ended March 31, 2026 results: net income Net loss totaled $13.6 million for the first quarter of 2026.

Period: the fiscal quarter ended March 31, 2026
Net income: Net loss totaled $13.6 million for the first quarter of 2026
Result: reported results

Exact text from the filing

Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 8, 2026 – Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Boundless Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-213269

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.